Where Will Biopharma Hiring Take Place in 2013?
Projections regarding where hiring will take place over the next few years show staffing will largely take place in the same areas as in 2009, according to BioPlan Associates' sixth annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. Production operations, process development, regulatory, and quality assurance and quality control will continue to be the job functions most in demand.
Hiring in 2013
Projections regarding where hiring will take place over the next five years show staffing will largely take place in the same areas as in 2009, with only a slightly greater percentage projected in process development and R&D hiring for the next five years (18.7%) compared to this year (15.6%).
Hiring in 2009
Over the next 12 months, biotherapeutic developers and CMOs will bring onboard a variety of new staff. Of these, 34% (compared to 33% last year) will be involved in production operations, and 15.6% (22% last year) will be involved in process development and R&D. "Other" will account for 8.3% of the new hires (19% last year). Regulatory or QA/QC departments will hire 15.8% of the new staff (15% last year).
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
